- Home
- TOPP vs KALA Comparison
TOPP vs KALA Comparison
Compare TOPP & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPP
- KALA
- Stock Information
- Founded
- TOPP 2014
- KALA 2009
- Country
- TOPP United States
- KALA United States
- Employees
- TOPP N/A
- KALA N/A
- Industry
- TOPP
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- TOPP
- KALA Health Care
- Exchange
- TOPP NYSE
- KALA Nasdaq
- Market Cap
- TOPP 26.6M
- KALA 26.2M
- IPO Year
- TOPP 2025
- KALA 2017
- Fundamental
- Price
- TOPP $1.74
- KALA $5.86
- Analyst Decision
- TOPP
- KALA Strong Buy
- Analyst Count
- TOPP 0
- KALA 3
- Target Price
- TOPP N/A
- KALA $14.00
- AVG Volume (30 Days)
- TOPP 6.7K
- KALA 123.2K
- Earning Date
- TOPP 08-11-2025
- KALA 08-05-2025
- Dividend Yield
- TOPP N/A
- KALA N/A
- EPS Growth
- TOPP N/A
- KALA N/A
- EPS
- TOPP N/A
- KALA N/A
- Revenue
- TOPP $16,117,227.00
- KALA N/A
- Revenue This Year
- TOPP N/A
- KALA N/A
- Revenue Next Year
- TOPP N/A
- KALA N/A
- P/E Ratio
- TOPP N/A
- KALA N/A
- Revenue Growth
- TOPP 0.44
- KALA N/A
- 52 Week Low
- TOPP $0.97
- KALA $2.92
- 52 Week High
- TOPP $4.50
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- TOPP N/A
- KALA 60.68
- Support Level
- TOPP N/A
- KALA $4.36
- Resistance Level
- TOPP N/A
- KALA $7.00
- Average True Range (ATR)
- TOPP 0.00
- KALA 0.71
- MACD
- TOPP 0.00
- KALA 0.16
- Stochastic Oscillator
- TOPP 0.00
- KALA 63.97
About TOPP TOPPOINT HOLDINGS INC
Toppoint Holdings Inc is a truckload services and solutions provider focused on the recycling export supply chain. The company operates in one operating segment where it derives its revenues from the delivery of truckload services.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.